5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?

(2010) Shayna L. Showalter et al.   CANCER BIOLOGY & THERAPY

S-1: a promising new oral fluoropyrimidine derivative

(2009) Muhammad Wasif Saif et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

(2008) J-L Lee et al.   BRITISH JOURNAL OF CANCER

Candidate mechanisms for capecitabine-related hand–foot syndrome

(2008) Gérard Milano et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

(2008) J. L. Yen-Revollo et al.   CLINICAL CANCER RESEARCH

Oral Fluoropyrimidines (Capecitabine or S-1) and Cisplatin as First Line Treatment in Elderly Patients with Advanced Gastric Cancer: A Retrospective Study

(2008) Y. M. Seol et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY